Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia. In addition to these clinical presentations, Nurix and its collaborators will also present new mechanistic insights into resistance to Bruton’s tyrosine kinase (BTK) targeted therapies at a separate ASH pos
Show less
Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswire
- Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
NRIX
Earnings
- 10/9/25 - Miss
NRIX
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 144
- 11/14/25 - Form SCHEDULE
- NRIX's page on the SEC website